 | • レポートコード：MRC2304J0034 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、227ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当市場調査レポートでは、世界のDTC（消費者直接型）遺伝子検査市場規模が、2021年1,477.98百万ドルから2022年1,728.32百万ドルへと成長し、更に年平均17.11％増大して2027年までに3,813.66百万ドルに達すると予測しています。当書は、DTC（消費者直接型）遺伝子検査の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（ミトコンドリアDNA検査、一塩基多型検査、Y染色体検査）分析、チャネル別（オフライン、オンライン）分析、結果別（祖先＆民族性、がん検診、遺伝性疾患キャリアステータス、新生児スクリーニング、特性）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、23andMe, Inc.、24Genetics、AlphaBiolabs Ltd、Ancestry.com LLC、Atlas Biomed、Chengdu 23Mofang Biotechnology Co., Ltd.、Color、Dante Labs, Inc.、EasyDNA、Family Tree DNA、Full Genomes Corporation, Inc.、Gene By Gene Ltd.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のDTC（消費者直接型）遺伝子検査市場規模：種類別 - ミトコンドリアDNA検査の市場規模 - 一塩基多型検査の市場規模 - Y染色体検査の市場規模 ・世界のDTC（消費者直接型）遺伝子検査市場規模：チャネル別 - オフラインチャネルの市場規模 - オンラインチャネルの市場規模 ・世界のDTC（消費者直接型）遺伝子検査市場規模：結果別 - 祖先＆民族性検査の市場規模 - がん検診の市場規模 - 遺伝性疾患キャリアステータス検査の市場規模 - 新生児スクリーニングの市場規模 - 特性検査の市場規模 ・世界のDTC（消費者直接型）遺伝子検査市場規模：地域別 - 南北アメリカのDTC（消費者直接型）遺伝子検査市場規模 アメリカのDTC（消費者直接型）遺伝子検査市場規模 カナダのDTC（消費者直接型）遺伝子検査市場規模 ブラジルのDTC（消費者直接型）遺伝子検査市場規模 ... - アジア太平洋のDTC（消費者直接型）遺伝子検査市場規模 日本のDTC（消費者直接型）遺伝子検査市場規模 中国のDTC（消費者直接型）遺伝子検査市場規模 インドのDTC（消費者直接型）遺伝子検査市場規模 韓国のDTC（消費者直接型）遺伝子検査市場規模 台湾のDTC（消費者直接型）遺伝子検査市場規模 ... - ヨーロッパ/中東/アフリカのDTC（消費者直接型）遺伝子検査市場規模 イギリスのDTC（消費者直接型）遺伝子検査市場規模 ドイツのDTC（消費者直接型）遺伝子検査市場規模 フランスのDTC（消費者直接型）遺伝子検査市場規模 ロシアのDTC（消費者直接型）遺伝子検査市場規模 ... - その他地域のDTC（消費者直接型）遺伝子検査市場規模 ・競争状況 ・企業情報 |
The Global Direct-to-Consumer Genetic Testing Market size was estimated at USD 1,477.98 million in 2021 and expected to reach USD 1,728.32 million in 2022, and is projected to grow at a CAGR 17.11% to reach USD 3,813.66 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Direct-to-Consumer Genetic Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing, and Y Chromosome Testing.
Based on Channel, the market was studied across Offline and Online.
Based on Result, the market was studied across Ancestry & Ethnicity, Cancer Screening, Genetic Disease Carrier Status, New Baby Screening, Traits, and Wellness. The Cancer Screening is further studied across Hereditary Cancer and Sporadic Cancer. The Hereditary Cancer is further studied across Blood Cancer, Breast Cancer, and Ovarian Cancer.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Direct-to-Consumer Genetic Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Direct-to-Consumer Genetic Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Direct-to-Consumer Genetic Testing Market, including 23andMe, Inc., 24Genetics, AlphaBiolabs Ltd, Ancestry.com LLC, Atlas Biomed, Chengdu 23Mofang Biotechnology Co., Ltd., Color, Dante Labs, Inc., EasyDNA, Family Tree DNA, Full Genomes Corporation, Inc., Gene By Gene Ltd., Genebase Systems, Genesis HealthCare, Helix, Identigene, L.L.C., Karmagenes, Laboratory Corporation of America, Inc., Living DNA, Mapmygenome, MyHeritage Ltd., Myriad Genetics, Inc., Pathway Genomics, Positive Biosciences, Ltd., Quest Diagnostics Incorporated, Shuwen Biotech Co. Ltd., Vitagene, Inc., and Xcode Life Sciences Pvt Ltd.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Direct-to-Consumer Genetic Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Direct-to-Consumer Genetic Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Direct-to-Consumer Genetic Testing Market?
4. What is the competitive strategic window for opportunities in the Global Direct-to-Consumer Genetic Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Direct-to-Consumer Genetic Testing Market?
6. What is the market share of the leading vendors in the Global Direct-to-Consumer Genetic Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Direct-to-Consumer Genetic Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Paradigm shift among consumers seeking greater control over their own healthcare
5.1.1.2. Rising awareness about genome testing and risk of genetic diseases
5.1.1.3. High aging population coupled with growing prevalence of chronic disorders
5.1.1.4. Increased inquisitiveness about the assessment of lineage and ancestry
5.1.2. Restraints
5.1.2.1. Related scientific, technical, and clinical issues
5.1.2.2. First amendment issues of honesty, fidelity to facts, and truth-in-advertising
5.1.3. Opportunities
5.1.3.1. Next-generation sequencing and bio-chip for present and future genetic diagnosis
5.1.3.2. Development of online applications to serve customer needs
5.1.4. Challenges
5.1.4.1. Complexity of test result interpretation
5.1.4.2. Lack of adequate physician knowledge about genetics and potential for genetic discrimination
5.2. Cumulative Impact of COVID-19
6. Direct-to-Consumer Genetic Testing Market, by Type
6.1. Introduction
6.2. Mitochondrial DNA Testing
6.3. Single Nucleotide Polymorphism Testing
6.4. Y Chromosome Testing
7. Direct-to-Consumer Genetic Testing Market, by Channel
7.1. Introduction
7.2. Offline
7.3. Online
8. Direct-to-Consumer Genetic Testing Market, by Result
8.1. Introduction
8.2. Ancestry & Ethnicity
8.3. Cancer Screening
8.4.1. Hereditary Cancer
8.4.2.1. Blood Cancer
8.4.2.2. Breast Cancer
8.4.2.3. Ovarian Cancer
8.4.2. Sporadic Cancer
8.4. Genetic Disease Carrier Status
8.5. New Baby Screening
8.6. Traits
8.7. Wellness
9. Americas Direct-to-Consumer Genetic Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Direct-to-Consumer Genetic Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Direct-to-Consumer Genetic Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 23andMe, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. 24Genetics
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AlphaBiolabs Ltd
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Ancestry.com LLC
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Atlas Biomed
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Chengdu 23Mofang Biotechnology Co., Ltd.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Color
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Dante Labs, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. EasyDNA
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Family Tree DNA
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Full Genomes Corporation, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Gene By Gene Ltd.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Genebase Systems
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Genesis HealthCare
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Helix
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Identigene, L.L.C.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Karmagenes
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Laboratory Corporation of America, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Living DNA
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Mapmygenome
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. MyHeritage Ltd.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Myriad Genetics, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Pathway Genomics
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Positive Biosciences, Ltd.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Quest Diagnostics Incorporated
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Shuwen Biotech Co. Ltd.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Vitagene, Inc.
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Xcode Life Sciences Pvt Ltd
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing